Akums Launches India’s First Ripasudil+Timolol Combo for Glaucoma and Ocular Hypertension

Apr 1, 2025

Ocular Hypertension, DCGI Approval, Ophthalmic Innovation
Ocular Hypertension, DCGI Approval, Ophthalmic Innovation

Source: Pharmabiz

Share:

Akums Drugs & Pharmaceuticals has launched a novel combination therapy of ripasudil and timolol for managing glaucoma and ocular hypertension. Approved by the DCGI, this marks the first Indian CDMO to bring such a formulation to market—offering a dual-action approach for improved eye pressure control.

Key Highlights

First-of-its-kind dual therapy in India

  • Akums becomes the first Indian contract development and manufacturing organisation (CDMO) to launch the ripasudil+timolol combination.

  • Approved by the Drugs Controller General of India (DCGI).

Stronger IOP control for glaucoma and ocular hypertension

  • Ripasudil improves fluid outflow through the trabecular meshwork.

  • Timolol reduces fluid production in the eye.

  • The dual mechanism provides more effective and sustained intraocular pressure (IOP) reduction.

Simplified treatment, better patient adherence

  • The single-drop combo simplifies glaucoma treatment regimens.

  • Improved ease of use is expected to enhance compliance, a key challenge in long-term glaucoma management.

Make-in-India push for ophthalmic innovation

  • Akums plans to use its advanced facilities to ensure consistent availability.

  • The initiative aligns with India’s goal of promoting self-reliant pharmaceutical innovation.

Statements from Leaders or Officials
 Sanjeev Jain, MD, Akums: “This innovation integrates two mechanisms to deliver better glaucoma outcomes. It’s part of our patient-first, Make-in-India approach to develop globally aligned, high-quality products.”
 Sandeep Jain, MD, Akums: “With rising glaucoma prevalence, improving efficacy and access is critical. This therapy offers both.”With nearly 11.9 million Indians affected by glaucoma, Akums’ ripasudil+timolol combination addresses a significant unmet need. By enhancing both efficacy and patient adherence, this launch could reshape the future of ophthalmic care in India.

Ocular Hypertension
DCGI Approval
Ophthalmic Innovation
Ocular Hypertension
DCGI Approval
Ophthalmic Innovation

Akums Launches India’s First Ripasudil+Timolol Combo for Glaucoma and Ocular Hypertension

Apr 1, 2025

Ocular Hypertension, DCGI Approval, Ophthalmic Innovation
Ocular Hypertension, DCGI Approval, Ophthalmic Innovation

Source: Pharmabiz

Akums Drugs & Pharmaceuticals has launched a novel combination therapy of ripasudil and timolol for managing glaucoma and ocular hypertension. Approved by the DCGI, this marks the first Indian CDMO to bring such a formulation to market—offering a dual-action approach for improved eye pressure control.

Key Highlights

First-of-its-kind dual therapy in India

  • Akums becomes the first Indian contract development and manufacturing organisation (CDMO) to launch the ripasudil+timolol combination.

  • Approved by the Drugs Controller General of India (DCGI).

Stronger IOP control for glaucoma and ocular hypertension

  • Ripasudil improves fluid outflow through the trabecular meshwork.

  • Timolol reduces fluid production in the eye.

  • The dual mechanism provides more effective and sustained intraocular pressure (IOP) reduction.

Simplified treatment, better patient adherence

  • The single-drop combo simplifies glaucoma treatment regimens.

  • Improved ease of use is expected to enhance compliance, a key challenge in long-term glaucoma management.

Make-in-India push for ophthalmic innovation

  • Akums plans to use its advanced facilities to ensure consistent availability.

  • The initiative aligns with India’s goal of promoting self-reliant pharmaceutical innovation.

Statements from Leaders or Officials
 Sanjeev Jain, MD, Akums: “This innovation integrates two mechanisms to deliver better glaucoma outcomes. It’s part of our patient-first, Make-in-India approach to develop globally aligned, high-quality products.”
 Sandeep Jain, MD, Akums: “With rising glaucoma prevalence, improving efficacy and access is critical. This therapy offers both.”With nearly 11.9 million Indians affected by glaucoma, Akums’ ripasudil+timolol combination addresses a significant unmet need. By enhancing both efficacy and patient adherence, this launch could reshape the future of ophthalmic care in India.

Share:

Ocular Hypertension
DCGI Approval
Ophthalmic Innovation
Ocular Hypertension
DCGI Approval
Ophthalmic Innovation